Failure of Vancomycin Continuous Infusion against Experimental Endocarditis Due to Vancomycin-IntermediateStaphylococcus aureus

Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

(2010) B. P. Howden et al.   CLINICAL MICROBIOLOGY REVIEWS

Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin

(2010) Y. K. Yoon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients

(2009) F. Pea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health‐System Pharmacists, and the Society of Infectious Diseases Pharmacists

(2009) Michael J. Rybak et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin

(2008) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy

(2008) P. R. Ingram et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

(2007) A. Soriano et al.   CLINICAL INFECTIOUS DISEASES